Agile Therapeutics Statistics Share Statistics Agile Therapeutics has 6.9M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 6.9M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 0% Shares Floating 5.14M Failed to Deliver (FTD) Shares 16 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 11.74K, so 0.17% of the outstanding
shares have been sold short.
Short Interest 11.74K Short % of Shares Out 0.17% Short % of Float 0.17% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.29 and the forward
PE ratio is 0.89.
Agile Therapeutics's PEG ratio is
0.
PE Ratio -0.29 Forward PE 0.89 PS Ratio 0.21 Forward PS 0.2 PB Ratio -0.26 P/FCF Ratio -0.44 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Agile Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.46,
with a Debt / Equity ratio of -0.13.
Current Ratio 0.46 Quick Ratio 0.33 Debt / Equity -0.13 Debt / EBITDA -0.11 Debt / FCF -0.23 Interest Coverage -14.01
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.03M Profits Per Employee $-761.32K Employee Count 19 Asset Turnover 1.91 Inventory Turnover 3.28
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 3.42% in the
last 52 weeks. The beta is 1.58, so Agile Therapeutics's
price volatility has been higher than the market average.
Beta 1.58 52-Week Price Change 3.42% 50-Day Moving Average 1.29 200-Day Moving Average 1.14 Relative Strength Index (RSI) 82.85 Average Volume (20 Days) 143,293
Income Statement In the last 12 months, Agile Therapeutics had revenue of 19.59M
and earned -14.46M
in profits. Earnings per share was -6.71.
Revenue 19.59M Gross Profit 10.62M Operating Income -19.88M Net Income -14.46M EBITDA -19.88M EBIT -13.05M Earnings Per Share (EPS) -6.71
Full Income Statement Balance Sheet The company has 2.56M in cash and 2.17M in
debt, giving a net cash position of 385K.
Cash & Cash Equivalents 2.56M Total Debt 2.17M Net Cash 385K Retained Earnings -423.17M Total Assets 14.96M Working Capital -11.79M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -9.58M
and capital expenditures 0, giving a free cash flow of -9.58M.
Operating Cash Flow -9.58M Capital Expenditures n/a Free Cash Flow -9.58M FCF Per Share -4.44
Full Cash Flow Statement Margins Gross margin is 54.18%, with operating and profit margins of -101.49% and -73.83%.
Gross Margin 54.18% Operating Margin -101.49% Pretax Margin -73.83% Profit Margin -73.83% EBITDA Margin -101.49% EBIT Margin -101.49% FCF Margin -48.88%
Dividends & Yields AGRX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for AGRX.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 11, 2023. It was a
backward
split with a ratio of 1:50.
Last Split Date Apr 11, 2023 Split Type backward Split Ratio 1:50
Scores Altman Z-Score -42.12 Piotroski F-Score 3
